CLDI
Income statement / Annual
Last year (2025), Calidi Biotherapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Calidi Biotherapeutics Inc's net income was -$19.91 M.
See Calidi Biotherapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$45.00 K |
$449.00 K |
$0.00 |
| Cost of Revenue |
$1.65 M
|
$0.00
|
$1.26 M
|
$274.00 K
|
$94.00 K
|
$0.00
|
| Gross Profit |
-$1.65 M
|
$0.00
|
-$1.26 M
|
-$229.00 K
|
$355.00 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
-5.09
|
0.79
|
0
|
| Research and Development Expenses |
$9.74 M
|
$8.88 M
|
$13.01 M
|
$7.26 M
|
$4.67 M
|
$3.18 M
|
| General & Administrative Expenses |
$10.50 M
|
$12.90 M
|
$15.98 M
|
$15.90 M
|
$6.16 M
|
$3.59 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
-$260.00 K
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.50 M
|
$12.90 M
|
$15.98 M
|
$15.64 M
|
$6.16 M
|
$3.59 M
|
| Other Expenses |
-$1.65 M
|
$0.00
|
-$1.26 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$18.59 M
|
$21.78 M
|
$27.74 M
|
$22.90 M
|
$10.84 M
|
$6.77 M
|
| Cost And Expenses |
$20.24 M
|
$21.78 M
|
$28.99 M
|
$23.17 M
|
$10.93 M
|
$6.77 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$207.00 K
|
$933.00 K
|
$3.75 M
|
$158.00 K
|
$614.00 K
|
$163.00 K
|
| Depreciation & Amortization |
$1.65 M
|
$1.54 M
|
$1.26 M
|
$260.00 K
|
$156.00 K
|
$107.00 K
|
| EBITDA |
-$18.59 M |
-$19.73 M |
-$24.20 M |
-$25.00 M |
-$9.45 M |
-$6.67 M |
| EBITDA Ratio |
0
|
0
|
0
|
-555.51
|
-21.05
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
-513.96
|
-23.35
|
0
|
| Total Other Income/Expenses Net |
$192.00 K
|
-$419.00 K
|
-$208.00 K
|
-$2.29 M
|
$13.88 M
|
-$1.16 M
|
| Income Before Tax |
-$20.05 M
|
-$22.20 M
|
-$29.20 M
|
-$25.42 M
|
$3.40 M
|
-$7.93 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-564.8
|
7.57
|
0
|
| Income Tax Expense |
$15.00 K
|
$14.00 K
|
$16.00 K
|
$11.00 K
|
$11.00 K
|
$4.00 K
|
| Net Income |
-$19.91 M
|
-$22.14 M
|
-$29.22 M
|
-$25.43 M
|
-$10.93 M
|
-$7.94 M
|
| Net Income Ratio |
0
|
0
|
0
|
-565.04
|
-24.35
|
0
|
| EPS |
-5.95 |
-35.7 |
-207.61 |
-358.8 |
14.16 |
-2.64 |
| EPS Diluted |
-5.95 |
-35.7 |
-207.61 |
-358.8 |
14.16 |
-2.64 |
| Weighted Average Shares Out |
$4.30 M
|
$664.42 K
|
$140.16 K
|
$70.59 K
|
$238.63 K
|
$2.98 M
|
| Weighted Average Shares Out Diluted |
$4.30 M
|
$664.42 K
|
$140.16 K
|
$70.59 K
|
$238.63 K
|
$2.98 M
|
| Link |
|
|
|
|
|
|
